Mesoblast Limited ( (AU:MSB) ) has provided an update.
Mesoblast Limited announced that its allogeneic cellular products, including Ryoncil and Revascor, are designated as ‘U.S. Country of Origin’ and will not be subject to U.S. tariffs on imported products. This designation, based on the products being manufactured from U.S. donors, allows Mesoblast to avoid potential cost increases and maintain competitive pricing in the U.S. market, potentially strengthening its position in the industry and providing reassurance to stakeholders about the stability of its operations.
More about Mesoblast Limited
Mesoblast Limited is a global leader in the development of allogeneic cellular medicines aimed at treating severe and life-threatening inflammatory conditions. Utilizing its proprietary mesenchymal lineage cell therapy technology platform, the company focuses on creating therapies that release anti-inflammatory factors to modulate the immune system and reduce inflammation. Mesoblast’s flagship product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease. The company is also developing additional therapies for other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.
YTD Price Performance: -37.73%
Average Trading Volume: 325,267
Technical Sentiment Signal: Sell
Current Market Cap: $1.54B
See more data about MSB stock on TipRanks’ Stock Analysis page.